Invesco Ltd. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,822,722
-33.5%
88,353
-4.9%
0.00%
-100.0%
Q2 2023$2,742,098
+43.5%
92,921
+12.0%
0.00%0.0%
Q1 2023$1,910,869
-22.6%
82,937
-6.5%
0.00%0.0%
Q4 2022$2,467,831
+3.3%
88,739
+13.9%
0.00%0.0%
Q3 2022$2,390,000
+10.2%
77,895
+5.7%
0.00%0.0%
Q2 2022$2,168,000
-0.4%
73,666
+8.9%
0.00%0.0%
Q1 2022$2,176,000
+9.7%
67,634
+52.1%
0.00%
Q4 2021$1,983,000
-18.5%
44,464
-7.8%
0.00%
-100.0%
Q3 2021$2,432,000
-91.9%
48,218
-87.4%
0.00%
-85.7%
Q2 2021$30,087,000
+1876.8%
383,565
+1339.1%
0.01%
Q1 2021$1,522,000
-91.5%
26,653
-87.5%
0.00%
-100.0%
Q4 2020$17,805,000
+58.1%
212,575
-32.4%
0.01%
+25.0%
Q3 2020$11,264,000
+60.9%
314,399
+8.6%
0.00%
+33.3%
Q2 2020$7,002,000
+37.8%
289,615
-0.2%
0.00%
+50.0%
Q1 2020$5,082,000
+53.2%
290,205
+52.3%
0.00%
+100.0%
Q4 2019$3,318,000
+13.3%
190,508
-0.3%
0.00%0.0%
Q3 2019$2,928,000
+17.9%
191,137
+59.8%
0.00%0.0%
Q2 2019$2,483,000
-11.6%
119,597
-1.2%
0.00%0.0%
Q1 2019$2,810,000
-18.0%
120,991
-27.0%
0.00%0.0%
Q4 2018$3,427,000
+81.7%
165,836
+91.2%
0.00%0.0%
Q3 2018$1,886,00086,7460.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Crestline Management, LP 19,462,500$339,037,00035.95%
Euclidean Capital LLC 323,749$27,117,0005.74%
Flagship Pioneering Inc. 2,730,263$228,687,0004.16%
Casdin Capital, LLC 1,310,000$109,726,0003.25%
A.R.T. Advisors, LLC 6,173$517,0002.39%
MARK ASSET MANAGEMENT LP 172,040$14,410,0001.73%
Temasek Holdings (Private) Ltd 4,410,457$369,420,0001.59%
Integral Health Asset Management, LLC 57,500$4,816,0001.43%
GILDER GAGNON HOWE & CO LLC 3,219,843$269,694,0001.34%
IRONWOOD INVESTMENT MANAGEMENT LLC 19,365$1,622,0000.95%
View complete list of DENALI THERAPEUTICS INC shareholders